In the Avatar trial, if all the data are legit and transparent, Anavex2-73 would have been approved (or close to) everywhere. Few medications, if any, for developmental diseases have an effect size of 2 (Cohen’s D) with statistical significance.
That's the problem and the reason for the street's response. He did not release all the data. If patients did better at week 4 and worse at week 7 compared to placebo, they were responders --- he needs to release the 7 week data and be transparent. Also Cohen D is used for comparison of mean +/- s.d. It has no meaning in categoric statistics - should have used phi.
Market Data 
Markets 
AI
